Novartis Ag ADR NVS

$160.50 +0.25 (0.16%)

Valuation

Market cap
306,258,400,000
Revenue TTM
$56,674,000,000
Net income TTM
$13,984,000,000
P/E (trailing)
18.03
P/E (forward)
17.61
Profit margin
24.67%
Debt to equity
1.23

Trading

Volume
1,417,400
Avg volume
2,200,460
Day's range
$159.48 – $160.84
Shares out
1,908,152,000
Stochastic %K
22%
Beta
0.40
Analysts
Hold
Price target
$153.90

Price

Company profile

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin d...

Show more

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
41 61 324 11 11
Website
https://www.novartis.com
Address
Lichtstrasse 35, Basel, Switzerland

Latest news

Stocktwits

fred898w Nov 15, 10:44 PM
$NVS back to 140
0 replies
DidYouReadThis Nov 14, 6:39 PM
For $KOD What’s your target #wholesale #acquisition #cost for 1 eye 1 time for wet age related macular degeneration closest to? #Comment your guess! $REGN $NVS $OTLK
0 replies
Biotechs2027 Nov 11, 6:13 PM
$NVS $CATX Novartis is active in the lead-212 (212Pb) radiopharmaceutical space as part of its broader investment in targeted alpha therapies (TATs) for cancer treatment.
1 replies
cheating_stock_trader Nov 10, 7:45 PM
$SRRK i would say with the zolgensma risk coming to home plate $NVS should want a piece of this not only for the chronic sma treatments but also for the glp1 backdoor. Srk439 Add also the fact that fshd trial is ongoing it is defensive for them to have a backup with del brax. 10b+ is a good starting number.
0 replies
Quantumup Nov 10, 1:44 PM
Piper Sandler reiterated $ARWR Overweight-$126 and said--ARWR Shares Hit on Pelacarsen Data @AHA, Limited Impact, Buyers on Weakness. [ $NVS $AMGN RHHBY SNY IONS] ARWR shares were down today on presentation of Novartis' failed Phase III LP(a) HORIZON trial of pelacarsen at AHA. Even if partner Amgen's Phase III OCEAN(a) trial fails, olpasiran accounts for <3% of our $126 Arrowhead price target. We are buyers on weakness for REDEMPLO, which could gain blockbuster SHTG approval in 2Q:27, Arrowhead's rich pipeline and strong balance sheet. At AHA, Arrowhead presented Phase I/Ila SAD data on ARO-DIMER-PA showing impressive dose-dependent lowering of LDLC up to 65% and triglycerides up to 78%. Arrowhead plans to submit the sNDA for REDEMPLO in SHTG by year-end, which has STAR designation from FDA and could gain approval in 2Q:27 for blockbuster U.S. launch. We estimate Arrowhead holds pro forma cash of ~$1.74 billion and owes $1.08 billion after refinancing Sixth Street debt.
0 replies
macrossluvsrobotech Nov 9, 5:13 PM
$LXRX INSIDER TIMELINE: WHY THE (The prior $NVS and $LLY Hi-Exec, now CEO of $LXRX) BOUGHT LAST FRIDAY Timeline behind CEO Dr. Mike Exton's insider buy vs. the new AHA data: 1. THE INSIDER PURCHASE DATE: Mike Exton executed his 30,064-share buy last FRIDAY (Nov 6) at $1.6631 on the open market. 2. WHEN WE FOUND OUT: We became aware of it THIS MORNING (Monday, Nov 9) when his SEC Form 4 hit EDGAR at 5:13 AM PST. 3. WHEN WAS THE AHA DATA RELEASED? The groundbreaking AHA cardiotranslational data was published TODAY (Nov 9) at 5:30 AM PST. 4. HOW "NEW" WAS THIS TO THE CEO? As CEO, Exton knew about these investigator-initiated AHA results & JACC paper for weeks during peer review & abstract prep. 5. THE LEGAL COMPLIANCE: Why no blackout violation? Lexicon's open trading window unlocked after Q3 earnings on Thursday, Nov 5. Because these are exploratory non-regulatory tests, it was a legal window to buy. Exton saw the Q3 beat, knew the AHA data was coming,& bought last Friday! $BIB
1 replies
GTA_Terminal Nov 8, 8:22 PM
Dark pool check on $NVS: what traded off the exchanges in the latest session. Price barely moved (+0.4%), which is what you'd expect if somebody big is building or unwinding a position quietly. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=NVS&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=NVS Read the full article for the full details: https://globaltradersacademy.com/articles/nvs-technical-levels-chart-options-flow-and-dark-pools-diverge-at-163?utm_source=stocktwits&utm_medium=social
0 replies
RonIsWrong Nov 8, 2:21 PM
$NVS $NVO (NYT) How Cardiologists’ High Hopes for Two Drugs Were Dashed By every measure, the drugs were no better than placebos, full data revealed on Saturday. Was it the fault of the design of the studies, or our very hypotheses about heart disease? Cardiologists have been on edge for months, waiting for the details surrounding recent reports of the stunning failures of two new heart drugs. The drugs — pelacarsen and ziltivekimab — were widely expected to usher in a new era in preventing heart disease. Companies, betting on the drugs’ promise, made huge investments in developing them. So when doctors saw preliminary announcements that the drugs were not helping patients in large clinical trials, many felt blindsided, although still hopeful that there was more to the story than they knew. “The whole cardiovascular community was gobsmacked,” said Dr. Karol Watson, a director of UCLA’s preventive cardiology program. Were the drugs close to succeeding, just barely missing a statistically significant benefit? Or were there at least subgroups of patients who were helped? Now the answers are in. There was not a shred of evidence that the drugs helped anyone. By every measure, they were no better than placebos. The results, Dr. Watson noted, “are about as neutral as they can be.” The full data were presented on Saturday morning at the annual meeting of the American Heart Association and in simultaneous publications in The New England Journal of Medicine. One drug, pelacarsen, by Novartis, is known to make levels of the Lp(a) blood protein plunge. The protein is widely believed to cause heart attacks and strokes. The other, ziltivekimab, by Novo Nordisk, stops inflammation, thought to be a major component of plaques in arteries. Neither drug made a dent in heart disease outcomes during these clinical trials. Dr. Paul Ridker of Mass General Brigham, who was the principal investigator for the inflammation trial — known as the Zeus study — had been a true believer.
1 replies